We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.48 | 0.63% | 76.28 | 76.27 | 76.64 | 76.49 | 75.43 | 76.47 | 9,026,089 | 22:49:09 |
From May 2019 to May 2024
By Sabela Ojea
AstraZeneca PLC said Monday that the U.S. Food and Drug Administration has requested further analysis of clinical data of its Roxadustat drug to complete the review of the new drug application.
The British-Swedish pharmaceutical giant said it will submit along with FibroGen, Inc. additional data to assist with the completion of labeling discussions.
The FTSE-100 listed company added that the new drug application is still under regulatory view, noting that the FDA has set a new action date of March 20, 2021.
The Roxadustat-drug is an oral inhibitor for patients with anemia of chronic kidney disease.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 21, 2020 02:29 ET (07:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
